ArticleGene therapy2015
Vpx-containing dendritic cell vaccine induces CTLs and reactivates latent HIV-1 in vitro.
Article in Gene therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 36 citations in OpenAlex.
- Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells.The Journal of infectious diseases · 2016Trial
- Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells.Nature biotechnology · 2026Article
- Type-1 inflammatory imprinting and programmed responsiveness to CD40L enhance Siglec-1-dependent HIV-1 trans-infection by dendritic cells.Frontiers in immunology · 2026Article
- Chimeric antigen receptor dendritic cells suppress melanoma growth in preclinical cancer models.Journal for immunotherapy of cancer · 2025Article
- Ionizing radiation-mediated dendritic cell maturation exacerbates inflammatory response of bone marrow mesenchymal stem cells and impairs osteogenesis in radiation-induced jaw injury.Stem cell research & therapy · 2025Article
- Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models.Journal for immunotherapy of cancer · 2024Article
- Cas9-mediated knockout of Ndrg2 enhances the regenerative potential of dendritic cells for wound healing.Nature communications · 2023Article
- Single-epitope T cell-based vaccine protects against SARS-CoV-2 infection in a preclinical animal model.JCI insight · 2023Article
- Autologous dendritic cell vaccination against HIV-1 induces changes in natural killer cell phenotype and functionality.NPJ vaccines · 2023Article
- Directly injected lentiviral vector-based T cell vaccine protects mice against acute and chronic viral infection.JCI insight · 2022Article
- Engaging innate immunity in HIV-1 cure strategies.Nature reviews. Immunology · 2022Review
- Type I Interferon Transcriptional Network Regulates Expression of Coinhibitory Receptors in Human T cells.Research square · 2021Article
- An Update on the HIV DNA Vaccine Strategy.Vaccines · 2021Review
- Efficient generation of isogenic primary human myeloid cells using CRISPR-Cas9 ribonucleoproteins.Cell reports · 2021Article
- xCT/SLC7A11 antiporter function inhibits HIV-1 infection.Virology · 2021Article
- Type I Interferon Transcriptional Network Regulates Expression of Coinhibitory Receptors in Human T cells.bioRxiv : the preprint server for biology · 2020Article
- Lentiviral-Vector-Based Dendritic Cell Vaccine Synergizes with Checkpoint Blockade to Clear Chronic Viral Infection.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- Role of Complement Receptors (CRs) on DCs in Anti-HIV-1 Immunity.Frontiers in immunology · 2020Review
- Generation of Powerful Human Tolerogenic Dendritic Cells by Lentiviral-Mediated IL-10 Gene Transfer.Frontiers in immunology · 2020Article
- The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook.Journal of immunology research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Eradication of human immunodeficiency virus-1 (HIV-1) from an infected individual requires a means of inducing production of virus from latently infected cells and stimulating an immune response against the infected cells. We report the development of lentiviral vectors that transduce dendritic cells (DCs) to both induce production of virus from latently infected cells and stimulate antigen-specific cytotoxic T lymphocytes (CTLs). The vectors package Vpx, a lentiviral accessory protein that counteracts the SAMHD1-mediated block to DC transduction, allowing for long-term expression of vector-encoded proteins. The vectors encode influenza or HIV-1-derived epitopes fused via a self-cleaving peptide to CD40L that releases the peptide into the endoplasmic reticulum for entry into the antigen presentation pathway. Expression of CD40L caused transduced DCs to mature and produce Th1-skewing cytokines. The DCs presented antigen to CD8 T cells, enhancing antigen-specific CTLs. Coculture of the transduced DCs with latently infected cells induced high-level virus production, an effect that was mediated by tumor necrosis factor alpha. The ability of a DC vaccine to reactivate latent HIV-1 and stimulate an adaptive immune response provide a means to reduce the size of the latent reservoir in patients. This strategy can also be applied to develop DC vaccines for other diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.